Grown Rogue International Reports Preliminary Full-Year Results

Grown Rogue Exceeds Revenue Estimates Amid Cannabis Market Volatility

Grown Rogue International (OTCQB: $GRIN) announced preliminary full-year 2023 financial results, reporting revenue of $125.4 million, an increase of 35% from the $92.9 million recorded in the prior fiscal year. This figure surpassed the consensus analyst estimate of $120 million, signaling robust operational performance in a challenging cannabis market. The company also indicated preliminary adjusted EBITDA of $28.1 million, a substantial 50% jump from $18.7 million in 2022.

The news propelled $GRIN shares higher, with the stock closing at $2.10, up 18.5% from its previous close of $1.77. Trading volume spiked to 1.7 million shares, nearly three times its 30-day average. The positive preliminary report provided a much-needed boost to investor confidence, which has been tempered by regulatory uncertainties and pricing pressures across the broader cannabis sector.

Market Impact

Grown Rogue International's stock price rallied sharply after the preliminary earnings release, marking its largest single-day percentage gain since July 2023, when the company announced a strategic acquisition. The 18.5% jump pushed $GRIN to its highest trading level since October 2022, adding approximately $25 million to its market capitalization, which now stands around $160 million. The upward momentum was sustained throughout the trading session, reflecting strong buying interest.

The positive sentiment extended beyond $GRIN, providing a halo effect for other multi-state operators (MSOs) and the broader cannabis industry. The AdvisorShares Pure US Cannabis ETF ($MSOS), which tracks U.S. cannabis companies, rose 3.1% on the day, closing at $7.55. This cross-asset spillover suggests that $GRIN's performance is being interpreted as a potential indicator of improving fundamentals within the U.S. cannabis market, particularly for companies with strong operational footprints in key states like Michigan and Oregon. Analysts noted that the significant revenue growth, coupled with improved EBITDA, signals a potential turning point for some MSOs struggling with profitability.

What Analysts Are Saying

Industry analysts largely responded positively to Grown Rogue's preliminary figures, though some maintained a cautious stance on the broader sector. According to Canaccord Genuity, who upgraded $GRIN to a "Buy" rating from "Hold," "Grown Rogue's preliminary results demonstrate strong execution and market penetration, particularly in its core markets. The 35% year-over-year revenue growth, coupled with expanding EBITDA margins, suggests a resilient business model capable of navigating current market headwinds." They raised their price target for $GRIN to $3.50 from $2.50, citing the company's operational efficiency and strategic positioning.

Conversely, Roth Capital Partners maintained a "Neutral" rating on $GRIN, acknowledging the impressive top-line growth but highlighting persistent industry-wide challenges. "While Grown Rogue's revenue figures are undoubtedly strong, the broader U.S. cannabis market continues to face significant regulatory uncertainty and pricing pressures," a Roth analyst noted. "The path to sustained, robust profitability for all MSOs remains challenging, and investors should monitor the final audited results for any material adjustments. Our price target remains $2.75." This perspective underscores the ongoing debate between company-specific performance and macro-level sector risks.

Stifel analysts offered a more tempered view, reiterating their "Hold" rating with a $2.20 price target. They stated, "Grown Rogue's preliminary results are encouraging, especially the EBITDA improvement. However, the cannabis industry is still in its nascent stages, subject to rapid shifts in consumer preferences and intense competition. While $GRIN has shown a commendable ability to grow, the long-term profitability trajectory will depend on sustained margin expansion and favorable regulatory developments at both state and federal levels." This highlights the importance of future catalysts beyond just strong earnings.

What to Watch

Investors will be closely monitoring several key factors following Grown Rogue's preliminary results. The first critical event is the release of the company's final audited financial statements, expected around March 15, 2024. Any significant deviations from the preliminary figures could impact investor sentiment. Analysts will scrutinize the detailed breakdown of costs, margins, and any adjustments to the reported EBITDA.

From a technical perspective, $GRIN shares now face immediate resistance at the $2.25 level, a price point not consistently breached since mid-2022. A sustained break above this could open the door for a retest of the $2.50 to $2.75 range, aligning with some analyst price targets. Conversely, the $1.95 level, which served as a ceiling for much of late 2023, now acts as immediate support; a fall below this could signal profit-taking.

Beyond company-specific metrics, broader regulatory developments in key U.S. states and at the federal level will remain crucial. Potential adult-use cannabis legalization efforts in states like Ohio or Pennsylvania, or any movement on federal rescheduling or descheduling of cannabis, could significantly alter the industry landscape and provide further tailwinds for MSOs like $GRIN. Any delays or setbacks in these legislative efforts, however, pose a significant risk that could temper the current optimism.